A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/20/2011	US20110257460 Capturing and delivering molecules in a mammal
10/20/2011	US20110257458 Method of using tumor cell debris to reduce brain tumor recurrence or growth
10/20/2011	US20110257405 Process for producing crystal
10/20/2011	US20110257271 Derivatives of dimethylcurcumin
10/20/2011	US20110257270 Drug for treatment of colon cancer
10/20/2011	US20110257263 Jasmonic acid compounds in cocoa products
10/20/2011	US20110257262 Crystalline ingenol mebutate
10/20/2011	US20110257261 Platinum (iv) complexes for use in dual mode pharmaceutical therapy
10/20/2011	US20110257254 Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor
10/20/2011	US20110257253 Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
10/20/2011	US20110257251 Telomerase inhibitors and methods of use thereof
10/20/2011	US20110257250 Treating Insulin Secreting Cells
10/20/2011	US20110257249 Drug carriers
10/20/2011	US20110257244 Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
10/20/2011	US20110257238 Heteroaryl Dihydroindolones as Kinase Inhibitors
10/20/2011	US20110257237 Process for the preparation of crystalline forms of sunitinib malate
10/20/2011	US20110257232 Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
10/20/2011	US20110257227 Methods For Treatment Of Cognitive And Menopausal Disorders With D-Threo Methylphenidate
10/20/2011	US20110257223 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
10/20/2011	US20110257222 Compounds and methods for the treatment of pain and other diseases
10/20/2011	US20110257219 Lower dosage strength pharmaceutical compositions forumlated with 3.75% imiquimod
10/20/2011	US20110257214 Morphinan compounds
10/20/2011	US20110257211 Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics
10/20/2011	US20110257208 Compounds useful as faah modulators and uses thereof
10/20/2011	US20110257207 Raf inhibitors
10/20/2011	US20110257206 Combinations of Therapeutic Agents for Treating Cancer
10/20/2011	US20110257203 Inhibitors of bruton's tyrosine kinase
10/20/2011	US20110257201 Agent for overcoming resistance to anti-cancer agent
10/20/2011	US20110257200 Treatment of Acne and Other Diseases
10/20/2011	US20110257196 Compounds for treatment of cancer
10/20/2011	US20110257190 Crystalline forms
10/20/2011	US20110257189 Pyrrolopyrazinone inhibitors of kinases
10/20/2011	US20110257187 Phthalazin-(2h)-one inhibitors of kinases
10/20/2011	US20110257185 Reverse-turn mimetics and method relating thereto
10/20/2011	US20110257184 Shp-2 phosphatase inhibitor
10/20/2011	US20110257181 Pyridazinone derivatives
10/20/2011	US20110257180 Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof
10/20/2011	US20110257178 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
10/20/2011	US20110257177 Benzylthiotetrazole inhibitors of store operated calcium release
10/20/2011	US20110257176 Nitrogen heterocycle derivatives as proteasome modulators
10/20/2011	US20110257173 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives
10/20/2011	US20110257172 3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives
10/20/2011	US20110257171 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
10/20/2011	US20110257170 4-morpholino-pyrido[3,2-d]pyrimidines
10/20/2011	US20110257167 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
10/20/2011	US20110257165 Bicyclic pyrazoles as protein kinase inhibitors
10/20/2011	US20110257157 Thiolactams and uses thereof
10/20/2011	US20110257155 Compounds and compositions as protein kinase inhibitors
10/20/2011	US20110257154 Compounds and compositions as protein kinase inhibitors
10/20/2011	US20110257152 Pyrrolopyridine inhibitors of kinases
10/20/2011	US20110257151 Novel 3,3-dimethyl tetrahydroquinoline derivatives
10/20/2011	US20110257143 Compositions and Method for the Treatment of Multiple Myeloma
10/20/2011	US20110257127 A2b adenosine receptor antagonists
10/20/2011	US20110257126 Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
10/20/2011	US20110257114 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyl-oxy)-phenyl] hexane
10/20/2011	US20110257112 Isolated compounds from phaleria macrocarpa as anti-cancer agents
10/20/2011	US20110257105 Synthetic peptide amides and dimers thereof
10/20/2011	US20110257102 Compositions and methods of treating cancer
10/20/2011	US20110257100 Inhibitors of Protein Tyrosine Kinase Activity
10/20/2011	US20110257096 Compositions for drug administration
10/20/2011	US20110257077 Compounds and compositions as channel activating protease inhibitors
10/20/2011	US20110256625 Liver Engrafting Cells, Assays, and Uses Thereof
10/20/2011	US20110256241 Methods and compositions for the treatment of cancer
10/20/2011	US20110256240 Combination Therapy
10/20/2011	US20110256236 Enhancement of the Anti-Leukemic Effect of Thalidomide
10/20/2011	US20110256225 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
10/20/2011	US20110256224 Methods and compositions for targeted delivery
10/20/2011	US20110256217 Pulsatile release compositions and methods for enhanced intestinal drug absorption
10/20/2011	US20110256215 Non-pegylated liposomal doxorubicin triple combination therapy
10/20/2011	US20110256214 Single-time vaccines
10/20/2011	US20110256212 Use of 8-Quinolinol and its Analogs to Target Cancer Stem Cells
10/20/2011	US20110256186 biomaterial based on wharton's jelly from the human umbilical cord
10/20/2011	US20110256175 Amino lipids and methods for the delivery of nucleic acids
10/20/2011	US20110256167 Immunostimulating saponins for use in situ tumor-destruction therapy
10/20/2011	US20110256164 Vaccine for the prevention of breast cancer recurrence
10/20/2011	US20110256162 Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
10/20/2011	US20110256161 Methods for enhancing immune response
10/20/2011	US20110256160 Adherent cells from placenta tissue and use thereof in therapy
10/20/2011	US20110256159 Adherent cells from placenta tissue and use thereof in therapy
10/20/2011	US20110256155 Methods to molecularly characterize circulating tumor cells
10/20/2011	US20110256154 Anti-erbb3 antibodies
10/20/2011	US20110256153 CD37-Binding Molecules and Immunoconjugates Thereof
10/20/2011	US20110256147 Diagnostic and treatment methods for cancer based on immune inhibitors
10/20/2011	US20110256146 Neuropilin antagonists
10/20/2011	US20110256144 Pharmaceutical composition for treatment and prevention of cancers
10/20/2011	US20110256143 FDF03 Antibodies and uses thereof
10/20/2011	US20110256142 Novel methods and antibodies for treating cancer
10/20/2011	US20110256139 Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor
10/20/2011	US20110256137 Pharmaceutical composition comprising a bispecific antibody for epcam
10/20/2011	US20110256133 Anti-polyubiquitin antibodies and methods of use
10/20/2011	US20110256132 Myostatin binding proteins
10/20/2011	US20110256130 Methods of treating inflammatory disorders
10/20/2011	US20110256129 Apoptosis promoters
10/20/2011	US20110256128 Triazole compounds as ksp inhibitors
10/20/2011	US20110256125 Materials and methods for improved immunoglycoproteins
10/20/2011	US20110256124 METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE
10/20/2011	US20110256123 Methods and uses of leptin in immune modulation and hepatocellular carcinoma
10/20/2011	US20110256119 Novel uses of grs proteins or fragments thereof
10/20/2011	US20110256117 Manufacturing and use of composite scaffolds
10/20/2011	US20110256115 Hydrosoluble [6)o-alpha-d-glcp-(1->]n-6-o-beta-d-glcp-(1->-phenolic derivatives with dermocosmetic, nutritional and therapeutic applications, and compositions containing said water soluble compounds

1 ... 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 ... 2211